bluebird bio Announces August Investor Event

Jul 31, 2020 08:00 am
CAMBRIDGE, Mass. -- 

bluebird bio, Inc. (NASDAQ: BLUE) today announced members of the management team will participate in the Canaccord Genuity 40th Annual Growth Conference, Wednesday, August 12, at 10:30 a.m. ET.

To access the live webcast of bluebird bio’s presentation, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. A replay of the webcast will be available on the bluebird bio website for 90 days following the event.

About bluebird bio, Inc.

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

bluebird bio is a human company powered by human stories. We’re putting our care and expertise to work across a spectrum of disorders including cerebral adrenoleukodystrophy, sickle cell disease, β-thalassemia and multiple myeloma, using three gene therapy technologies: gene addition, cell therapy and (megaTAL-enabled) gene editing.

bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland. For more information, visit bluebirdbio.com.

Follow bluebird bio on social media: @bluebirdbio, LinkedIn, Instagram and YouTube.

bluebird bio is a trademark of bluebird bio, Inc.

Investors & Media
Investors:
Ingrid Goldberg, 410-960-5022
[email protected]
OR
Elizabeth Pingpank, 617-914-8736
[email protected]

Media:
Jenn Snyder, 617-448-0281
[email protected]